YAP is involved in resistance to a variety of chemotherapeutic drugs in several cancer types, including molecular targeted drugs such as inhibitors of CDK4/6, EGFR and BRAF [22,23,24], as well as classical cytotoxic drugs such as 5-FU, cisplatin (CDDP) and doxorubicin [25,26,27]. The gene discussed is EGFR; the disease is cancer.